BACKGROUND: The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma (DLBCL) remains to be defined. We aimed to compare CHOP plus rituximab (R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients. METHODS: Between 2003 and 2009, 140 untreated patients with stage I DLBCL were retrospectively analyzed in this study. RESULTS: Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group. Ninety-one patients received additional radiotherapy at the end of chemotherapy. The different treatment groups were well-balanced with respect to baseline characteristics. Complete response (CR) rate was 77% both in R-CHOP and CHOP groups (P=0.945). After a median follow-up period of 56 months, patients received R-CHOP regimen had similar 5-year progression-free survival (PFS) (76% vs. 85%; log-rank P=0.215) and 5-year overall survival (OS) (90% vs. 96%; log-rank P=0.175) compared with those with CHOP alone. Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone (86% vs. 71%; log-rank P=0.005). At multivariate analysis, patients who had CR (P=0.008) and received radiotherapy (P=0.003) were significantly associated with superior PFS. CONCLUSIONS: CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients.
BACKGROUND: The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma (DLBCL) remains to be defined. We aimed to compare CHOP plus rituximab (R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients. METHODS: Between 2003 and 2009, 140 untreated patients with stage I DLBCL were retrospectively analyzed in this study. RESULTS: Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group. Ninety-one patients received additional radiotherapy at the end of chemotherapy. The different treatment groups were well-balanced with respect to baseline characteristics. Complete response (CR) rate was 77% both in R-CHOP and CHOP groups (P=0.945). After a median follow-up period of 56 months, patients received R-CHOP regimen had similar 5-year progression-free survival (PFS) (76% vs. 85%; log-rank P=0.215) and 5-year overall survival (OS) (90% vs. 96%; log-rank P=0.175) compared with those with CHOP alone. Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone (86% vs. 71%; log-rank P=0.005). At multivariate analysis, patients who had CR (P=0.008) and received radiotherapy (P=0.003) were significantly associated with superior PFS. CONCLUSIONS:CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients.
Entities:
Keywords:
Diffuse large B-cell lymphoma (DLBCL); R-CHOP; prognosis; radiotherapy; stage I
Authors: Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan Journal: Clin Cancer Res Date: 2011-09-20 Impact factor: 12.531
Authors: Jack Phan; Ali Mazloom; L Jeffrey Medeiros; Tony G Zreik; Christine Wogan; Ferial Shihadeh; Maria Alma Rodriguez; Luis Fayad; Nathan Fowler; Valerie Reed; Patrecia Horace; Bouthaina Shbib Dabaja Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Michael Pfreundschuh; Anthony D Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier-Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt Journal: Lancet Oncol Date: 2008-04-08 Impact factor: 41.316
Authors: Ari Ballonoff; Kyle E Rusthoven; Amanda Schwer; Robert McCammon; Brian Kavanagh; Michael Bassetti; Francis Newman; Rachel Rabinovitch Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-19 Impact factor: 7.038
Authors: Daniel O Persky; Joseph M Unger; Catherine M Spier; Baldassarre Stea; Michael LeBlanc; Matthew J McCarty; Lisa M Rimsza; Richard I Fisher; Thomas P Miller Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544